恆智動科技股份有限公司
Update：2026/11/11
Industries
Main Industry
Health Care
Main Product/Service
PapiVax’s product pipeline focuses on therapeutic vaccines against HPV infection and related cancers (e.g. cervical, head‑and‑neck cancers), with several candidates such as PVX‑4, PVX‑7, and PVX‑8 already in clinical‑trial stages; the company also offers
The content above was translated by Ai
Founded Year
2025
Unified Business No.
96819818
Status
Active
Number of Employees
0
Total Paid-in
Capital
610,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
PapiVax Biotech, Inc., founded in 2013 and headquartered in Taipei with a subsidiary in the United States, is a biotech company specializing in nucleic‑acid immunotherapy using proprietary DNA‑plasmid vector and delivery platforms — aiming to become a glo
The content above was translated by Ai
